Document Detail


New developments in the treatment of hypoplastic left heart syndrome.
MedLine Citation:
PMID:  15249913     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Hypoplastic left heart syndrome (HLHS) was once a uniformly fatal disease, accounting the majority of neonatal deaths due to congenital heart defects. Twenty-five years of advances in the surgical and medical management of this disease have resulted in dramatic improvements in survival for these children. The goal for patients with HLHS should be survival of near 100% with a good quality of life. The advances described in this manuscript detail some of the new techniques used in the surgical and medical management. For infants undergoing staged reconstruction, the Norwood procedure is performed in the newborn period, followed by a hemi-Fontan operation at 6 months of age, and a modified Fontan operation at 1 to 2 years of age. A significant recent modification of the Norwood procedure is the placement of a right ventricle to pulmonary artery (RV-PA) conduit instead of a systemic artery to pulmonary shunt (modified Blalock-Taussig or BT shunt) as the source of pulmonary blood flow. Our recent experience with this modification demonstrated an incremental increase in survival, improved postoperative stability, and decreased inter-stage mortality. At catheterization, significant differences in hemodynamic parameters were present that were consistent with improved coronary blood flow, decreased volume load to the single right ventricle, and improved pulmonary artery growth in those patients with the RV-PA conduit. The 3rd stage in the surgical treatment of HLHS is the modified Fontan operation or cavo-pulmonary anastamosis. A new approach for Fontan completion is the placement of a stent covered with a thin layer of Goretex from the inferior vena cava to the hemi-Fontan baffle. This can be performed in the catheterization laboratory, with a decrease in post-procedure pleural effusions, lower mortality, and a shorter length of stay. The future of treatment for HLHS may eventually involve a single open-heart procedure with initial and final interventions being performed in the catheterization laboratory. Some cardiac centers perform transplantation for management of HLHS. Survival following transplantation has improved as advances in the pre- and post-operative management continue, along with new options for immunosuppression. Treatment for HLHS continues to evolve, as ongoing work has resulted in improved short and long-term survival. The future for children with this disease is encouraging as evidenced by the remarkable achievements made to date and the current worldwide interest and study of HLHS.
Authors:
K O Maher; S S Gidding; J M Baffa; C Pizarro; W I Norwood
Related Documents :
8317413 - Rupture and migration of the venous segment of leveen shunt: an unreported complication.
10588113 - Transcranial doppler of a paradoxical brain embolism associated with a pulmonary arteri...
8447303 - A new vascular access catheter for hemodialysis.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Minerva pediatrica     Volume:  56     ISSN:  0026-4946     ISO Abbreviation:  Minerva Pediatr.     Publication Date:  2004 Feb 
Date Detail:
Created Date:  2004-07-13     Completed Date:  2004-08-26     Revised Date:  2006-03-28    
Medline Journal Info:
Nlm Unique ID:  0400740     Medline TA:  Minerva Pediatr     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  41-9     Citation Subset:  IM    
Affiliation:
Nemours Cardiac Center, duPont Hospital for Children, Wilmington, DE 19899, USA. kmaher@nemours.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cardiac Surgical Procedures / trends*
Child, Preschool
Humans
Hypoplastic Left Heart Syndrome / surgery*
Infant

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Three-dimensional echocardiography in children with atrial septal defect.
Next Document:  Recent developments and controversies in Kawasaki disease.